Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Hypothermic Oxygenated Machine Perfusion Hopedhope

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Completed1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07674394Not ApplicableNot Yet Recruiting

New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.

NCT02798861Completed

Controlled Attenuation Parameter (CAP) in Liver Allografts

Showing all 2 trials

Research Network

Common Treatments

  • Hypothermic Oxygenated Machine Perfusion Hopedhope1
  • Fibroscan 4025301

Active Sponsors

  • Andres Duarte-Rojo1
  • The Mediterranean Institute for Transplantation and Advanced Specialized Therapies1

Top Investigators

Related Conditions

  • Early Allograft Dysfunction2
  • Liver Transplant1
  • Liver Transplantation Lt1
  • Liver Steatosis1
  • Ischemiareperfusion Injury1

Activity Timeline